| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/02/2005 | CA2479613A1 Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them |
| 03/01/2005 | US6861447 Method for producing a coenzyme Q10/γ-cyclodextrin complex |
| 03/01/2005 | US6861439 Treatment of cerebrovascular disease |
| 03/01/2005 | US6861438 7-oxo-4,7-dihydro-thieno(3,2-b)pyridine-6-carboxylic acid benzylamide derivatives; herpes viricides |
| 03/01/2005 | US6861437 Substituted imidazo [1,2-a] pyridine derivatives |
| 03/01/2005 | US6861430 β-carboline derivatives and its pharmaceutical use against depression and anxiety |
| 03/01/2005 | US6861429 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
| 03/01/2005 | US6861425 Benzimidazole compounds as ORL1-receptor agonists |
| 03/01/2005 | US6861418 Modulating protein kinase signal transduction; anticancer agents |
| 03/01/2005 | US6861417 Such as 2-(4-fluorophenyl)-3-(pyridin-4-yl)pyrazine for treating cytokine mediated diseases such as psoriatic arthritis |
| 03/01/2005 | US6861407 Methods of therapy with thrombin derived peptides |
| 03/01/2005 | US6861406 Use of peptides or small molecules in treatment of disease, in high-throughput screening, in use of metal-binding peptides derived from sequences present in CD74-homology domain of insulin-like growth factor |
| 03/01/2005 | US6861404 Therapies for chronic renal failure |
| 03/01/2005 | US6861233 Method of screening for triacyglycerol hydrolase inhibitors |
| 03/01/2005 | US6861072 Pharmaceutical composition with gastric residence and controlled release |
| 03/01/2005 | US6861054 suPAR stimulating activity of tcuPA-mediated fibrinolysis and different uses thereof |
| 03/01/2005 | CA2196174C Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes |
| 02/24/2005 | WO2005016965A1 Modulators of the potassium channels twik-1, task-1, girk1, sk2 or pcn1, used to treat arrhythmia, coronary heart disease or hypertension |
| 02/24/2005 | WO2005016928A1 Imidazopyridine derivatives |
| 02/24/2005 | WO2005016885A2 COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE |
| 02/24/2005 | WO2005016870A1 2-substituted benzoic acid derivatives as hm74a receptor agonists |
| 02/24/2005 | WO2005016400A1 Endoluminal prosthesis comprising a therapeutic agent |
| 02/24/2005 | WO2005016338A1 Use of 5-ht2b receptor antagonists for the treatment of congestive heart failure |
| 02/24/2005 | WO2005016337A1 Channel blocking compounds |
| 02/24/2005 | WO2005016335A1 Indoline-sulfanilic acid amides used as ppar delta modulators |
| 02/24/2005 | WO2005016334A1 Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1 |
| 02/24/2005 | WO2004087195A3 Therapeutic use of modulators of notch and/or kruppel-like factors |
| 02/24/2005 | WO2004082593A3 Pharmaceutical compositions of cetp inhibitors |
| 02/24/2005 | WO2004024088A3 Design of chemokine analogs for the treatment of human diseases |
| 02/24/2005 | WO2004002472A8 Carvedilol hydrobromide |
| 02/24/2005 | WO2003018758A3 Reagents and methods for smooth muscle therapies |
| 02/24/2005 | US20050043788 Drug-eluting stent |
| 02/24/2005 | US20050043787 Medical device with coating that promotes endothelial cell adherence |
| 02/24/2005 | US20050043536 Sulfonamides |
| 02/24/2005 | US20050043535 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists |
| 02/24/2005 | US20050043534 Modulators of ceramidase and methods of used based thereon |
| 02/24/2005 | US20050043408 Prevent protein glycation; drug screening; using epinephrine compound |
| 02/24/2005 | US20050043395 Angiogenesis inhibitors; reduced vascular system permeability; anticancer agents; antitumor agents |
| 02/24/2005 | US20050043394 For prophylaxis and therapy of diabetes mellitus, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases, neuropathic diseases, neuropathic pain and polyneuropathy; free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate, deoxyuridine monophosphate |
| 02/24/2005 | US20050043393 Antilipemic agents |
| 02/24/2005 | US20050043386 2-amino-2-(ethyl or methyl)-4-{5-substituted pyrrol-2-yl}butan-1-ols, phosphates and phosphonates; antiarthritic agents; psoriasis; immunosuppressants |
| 02/24/2005 | US20050043362 Use of compounds |
| 02/24/2005 | US20050043350 Administering heterocyclic ether such as 5-chloro-7-hydroxy-3-(4-hydroxyphenylz)-4-oxo-1-benzopyran for prophylaxis of Alzheimer's disease, osteoporosis, cardiovascular disorders, psychological disorders, antiarthritic agents,anxiolytic agents |
| 02/24/2005 | US20050043346 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/24/2005 | US20050043341 For stimulation of reverse cholesterol transport, lowering low density lipoproteins in blood; for treatment of hypolipoproteinaemia, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, arteriosclerosis adiposity and obesity stroke or Alzheimer's disease |
| 02/24/2005 | US20050043336 Quinazoline derivatives as antitumor agents |
| 02/24/2005 | US20050043335 Heterocyclic derivatives of glycinamide and their medical use |
| 02/24/2005 | US20050043333 Quinazolinone derivative |
| 02/24/2005 | US20050043332 Such as 4 (cis-3-hydroxycyclopentyl)amino-5,6-dimethyl-2-phenyl-7H-pyrrolo[2,3d] pyrimidine for treatment of adenosine receptor stimulated diseases, cardiovascular disorders, and nervous system disorders |
| 02/24/2005 | US20050043328 Such as 6-(2-hydroxy-3-chloroxybenzylamino)purine, 6-(2-hydroxy-4-chlorobenzylamino)purine; agriculture; cloning; immunostimulation |
| 02/24/2005 | US20050043318 Such as (2R,5S)-1-((4-chloro-2-(aminocarbonyl)phenoxy)methyl)carbonyl-2,5-dimethyl4-(4-fluorobenzyl)piperazine |
| 02/24/2005 | US20050043305 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 02/24/2005 | US20050043304 Lower alkyl molecular weight amine as enzyme inhibitors for use in the treatment of tryptase enzyme inhibitors inhibitorsfor respiratory system disorders, antiinflammatory agents, inflammatory bowel disease, hyperprolific skin disorders, vascular edema and rheumatoid arthritis |
| 02/24/2005 | US20050043303 prophylaxis of cardiovascular disorders comprising administering to mammals inhibitors of cyclic guanosine monophosphate metabolizing phosphodiesterases such as 2-{2-Ethoxy-5-[4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl]-phenyl}-6-methyl-8-propyl-3H-imidazo[1,5-a][1,3,5]triazin-4-one; antiarrythmic agents |
| 02/24/2005 | US20050043302 New indole derivatives as factor Xa inhibitors |
| 02/24/2005 | US20050043295 Pharmaceutically effective compounds |
| 02/24/2005 | US20050043293 Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 02/24/2005 | US20050043281 administering for treatment of metabolic bone diseases, mobilizing calcium for osteoporosis, imbalances in the immune system |
| 02/24/2005 | US20050043274 Pharmaceutical compositions and methods for lowering blood pressure and pulse rate |
| 02/24/2005 | US20050043269 Pharmaceutically active uridine esters |
| 02/24/2005 | US20050043241 Use of inhibitors of given amino acid sequence; inhibit phosphorylation of a transcription factor; can be used to treat or prevent diabetes, ionizing radiation damage, autoimmune diseases, ischemia/reperfusion injuries, heart hypertrophies, cancer |
| 02/24/2005 | US20050043238 Exendin formulations for weight reduction |
| 02/24/2005 | US20050043228 Glp-1 formulations with protracted time action |
| 02/24/2005 | US20050042738 Carbohydrate-associated proteins |
| 02/24/2005 | US20050042731 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders |
| 02/24/2005 | US20050042671 Modulation of angiogenesis |
| 02/24/2005 | US20050042614 Point mutations; dipeptidyl-peptidase inhibitors; kits |
| 02/24/2005 | US20050042318 Controlling hormone sensitive diseases; solvent extraction of hops, filtration, desolventizing |
| 02/24/2005 | US20050042317 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/24/2005 | US20050042311 Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells |
| 02/24/2005 | US20050042273 Covalently linking PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; diagnostic and therapeutic agent; improving pharmacokinetic properties |
| 02/24/2005 | US20050042237 Method for administering a spill resistant pharmaceutical system |
| 02/24/2005 | US20050042202 Gentamicin, amikacin, tobramycin, netilmicin, cephalosporin, ceftazidine, maxalactam, carbopenem, imipenem, aztreonam, ampicillin, penicillin, ureidopenicillin, augmentin, amphotericin, famvir and/or acyclovir; and Vpr protein, fragment or nucleic acid encoding; systemic inflammatory response syndrome |
| 02/24/2005 | US20050042201 Synergistic mixture of glycoprotein and angiogenesis inhibitor comprising angiostatin, thrombostatin, endostatin, interferon, interferon-inducible factor 10, platelet factor, and/or cyclooxygenase inhibitor; antitumor and anticarcinogenic agents |
| 02/24/2005 | US20050042173 Pharmaceuticals, cosmetics or nutraceuticals with a bioadhesive and plasticizer on a biodegradable support for transdermal or transmucosal application |
| 02/24/2005 | DE10335566A1 Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen Azolyl carbinols containing drug derivatives of aryl (or heteroaryl) |
| 02/24/2005 | CA2762015A1 Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| 02/24/2005 | CA2536961A1 Endoluminal prosthesis comprising a therapeutic agent |
| 02/24/2005 | CA2536146A1 Splice variants of erbb ligands, compositions and uses thereof |
| 02/24/2005 | CA2535620A1 6-substituted anilino purines as rtk inhibitors |
| 02/24/2005 | CA2535416A1 Imidazopyridine derivatives |
| 02/24/2005 | CA2535178A1 Channel blocking compounds |
| 02/24/2005 | CA2525647A1 Synthetic chemokine receptor ligands and methods of use thereof |
| 02/23/2005 | EP1508570A1 Novel physiolgically active substances |
| 02/23/2005 | EP1508566A1 (2s)-2-ethylphenylpropionic acid derivative |
| 02/23/2005 | EP1508561A1 2-(a-HYDROXYPENTYL) BENZOATE AND ITS PREPARATION AND USE |
| 02/23/2005 | EP1508340A1 Insulin resistance improving agents |
| 02/23/2005 | EP1508332A1 Medicinal composition |
| 02/23/2005 | EP1507855A2 Elongase genes and uses thereof |
| 02/23/2005 | EP1507780A1 Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| 02/23/2005 | EP1507779A1 Inhibitors of jak and cdk2 protein kinases |
| 02/23/2005 | EP1507776A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| 02/23/2005 | EP1507773A1 Macrocyclic compounds useful as pharmaceuticals |
| 02/23/2005 | EP1507767A1 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2b and alpha-2c adrenergic receptors |
| 02/23/2005 | EP1507765A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 02/23/2005 | EP1507764A1 Novel enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts, their preparations and pharmaceutical compositions |
| 02/23/2005 | EP1507763A1 Tetrahydroisoquinoline derivatives |
| 02/23/2005 | EP1507758A2 Indole derivatives and their use as ligands for cb2 receptors |
| 02/23/2005 | EP1507756A1 Ccr9 inhibitors and methods of use thereof |
| 02/23/2005 | EP1507754A1 Alkoxy aryl beta-2 adrenergic receptor agonists |